Immune organoid technology to study human vaccine and infection responses
Official title: Advancing immune organoid technology and organoid combinations
Funded at Stanford University · NIH-11591271 · Data updated 2026-11-12
Researchers at Stanford are expanding human immune organoids to better understand how the immune system responds to vaccines and infections, using spleen-derived tissues and advanced sequencing.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project start | September 1, 2003 |
| Project end | April 30, 2029 |
| Funding year | 2026 |
| Award (this year) | $1,795,320 |
| NIH project number | 3U19AI057229-23S1 |
| Project ID | NIH-11591271 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates include individuals from whom donor spleen, skin, blood, and lung samples are obtained for organoid development; future clinical translation would involve individuals receiving vaccines or experiencing infections.
✕Less likely to help
Patients without access to vaccines or with conditions not represented in the organoid models may not directly benefit.
What this research studies
This project develops and refines human immune organoids to model how vaccines like flu and SARS-CoV-2 elicit immune responses. It will optimize RNA vaccine protocols using spleen organoids and compare organoid results with data from real human studies. The team will analyze BCR and TCR repertoires to gain deeper insights into immune activation. They will also test responses to the Yellow Fever vaccine to achieve complete T and B cell activity, and explore multimerized peptide-MHC reagents to improve immune cell detection.
Why it matters
Potential benefit: If successful, patients could benefit from more accurate models of vaccine responses that inform safer and more effective vaccines.
How similar studies have gone: Previous work with immune organoids has shown promise in modeling human immune responses and vaccine reactions.
Where this research is happening
-
Stanford University
Stanford, United States Active
Researchers
- Principal investigator: Davis, Mark Morris — Stanford University
- Study coordinator: Davis, Mark Morris
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.